Today, biologists and medicinal chemists realize that there is a strong relationship between pharmacodynamic (what the drug does to the organism) and pharmacokinetic (what the organism does to the drug) effects. A significant contributing factor to the evolution in drug discovery was the methodological and technological revolution with the advent of combinatorial chemistry, high-throughput screening and profiling, and in silico prediction of target-based activity and ADMET (absorption, distribution, metabolism, excretion and toxicity) properties. High-throughput screening and in silico methods have accelerated the process towards drugability of new chemical structures. Another component of the revolution in drug discovery is the replacement of the disease (indication)-based approach by a target-based approach. A better understanding of pathophysiology of diseases and the underlying biological processes of diseases combined with explosive development of genomics and proteomics have been instrumental in the birth of this new paradigm. This volume summarizes discussions of these three aspects of modern drug discovery, i.e. priority for targets, early ADMET assessment, and in silico screening. We trust that readers from academia as well as from industry will benefit from these studies.
"Sinopsis" puede pertenecer a otra edición de este libro.
Today, biologists and medicinal chemists realize that there is a strong relationship between pharmacodynamic (what the drug does to the organism) and pharmacokinetic (what the organism does to the drug) effects. A significant contributing factor to the evolution in drug discovery was the methodological and technological revolution with the advent of combinatorial chemistry, high-throughput screening and profiling, and in silico prediction of target-based activity and ADMET (absorption, distribution, metabolism, excretion and toxicity) properties. High-throughput screening and in silico methods have accelerated the process towards drugability of new chemical structures. Another component of the revolution in drug discovery is the replacement of the disease (indication)-based approach by a target-based approach. A better understanding of pathophysiology of diseases and the underlying biological processes of diseases combined with explosive development of genomics and proteomics have been instrumental in the birth of this new paradigm. This volume summarizes discussions of these three aspects of modern drug discovery, i.e. priority for targets, early ADMET assessment, and in silico screening. We trust that readers from academia as well as from industry will benefit from these studies.
"Sobre este título" puede pertenecer a otra edición de este libro.
Librería: Antiquariat Thomas Haker GmbH & Co. KG, Berlin, Alemania
Hardcover. Condición: Wie neu. 1st ed. 268 S. Like new. Shrink wrapped. Sprache: Englisch Gewicht in Gramm: 825. Nº de ref. del artículo: 821673
Cantidad disponible: 1 disponibles
Librería: moluna, Greven, Alemania
Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. KlappentextrnrnA significant contributing factor to the evolution in drug discovery was the methodological and technological revolution with the advent of combinatorial chemistry. This volume summarizes discussions of three aspects of modern dru. Nº de ref. del artículo: 3566001786
Cantidad disponible: Más de 20 disponibles
Librería: preigu, Osnabrück, Alemania
Buch. Condición: Neu. Virtual ADMET Assessment in Target Selection and Maturation | B. Testa (u. a.) | Buch | Englisch | 2006 | IOS Press | EAN 9781586037031 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. Nº de ref. del artículo: 135872043
Cantidad disponible: 5 disponibles
Librería: Books Puddle, Woodside, NY, Estados Unidos de America
Condición: New. pp. x + 255 1st Edition. Nº de ref. del artículo: 26480488
Cantidad disponible: 4 disponibles
Librería: Revaluation Books, Exeter, Reino Unido
Hardcover. Condición: Brand New. 1st edition. 255 pages. 9.25x6.50x0.75 inches. In Stock. Nº de ref. del artículo: x-158603703X
Cantidad disponible: 2 disponibles
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Today, biologists and medicinal chemists realize that there is a strong relationship between pharmacodynamic (what the drug does to the organism) and pharmacokinetic (what the organism does to the drug) effects. A significant contributing factor to the evolution in drug discovery was the methodological and technological revolution with the advent of combinatorial chemistry, high-throughput screening and profiling, and in silico prediction of target-based activity and ADMET (absorption, distribution, metabolism, excretion and toxicity) properties. High-throughput screening and in silico methods have accelerated the process towards drugability of new chemical structures. Another component of the revolution in drug discovery is the replacement of the disease (indication)-based approach by a target-based approach. A better understanding of pathophysiology of diseases and the underlying biological processes of diseases combined with explosive development of genomics and proteomics have been instrumental in the birth of this new paradigm. This volume summarizes discussions of these three aspects of modern drug discovery, i.e. priority for targets, early ADMET assessment, and in silico screening. We trust that readers from academia as well as from industry will benefit from these studies. Nº de ref. del artículo: 9781586037031
Cantidad disponible: 1 disponibles
Librería: Biblios, Frankfurt am main, HESSE, Alemania
Condición: New. PRINT ON DEMAND pp. x + 255. Nº de ref. del artículo: 18480482
Cantidad disponible: 4 disponibles
Librería: Majestic Books, Hounslow, Reino Unido
Condición: New. Print on Demand pp. x + 255 Illus. Nº de ref. del artículo: 7400247
Cantidad disponible: 4 disponibles